2nd Annual Pharma Pricing, Reimbursement & Market Access 2016
Offering our customers the knowledge and connections for a profitable business

    MARCO PENSKE Boehringer Ingelheim






    OMAR ALI QIPP Adviser Payer Network


    STEINAR MADSEN Norwegian Medicines Agency




    OLIVER STAHL Eli Lilly


    KEN WALSH Evidera




    PATRICK MOLLON Health-Economics & Outcomes Research Consultant


    OYVIND MELIEN Norwegian Directorate of Health


    W. NEIL PALMER PDCI Market Access


    SANDY EISEN Frontline Pharma Consulting


    ALEXANDER NATZ European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)


    LESLIE GALLOWAY Ethical Medicines Industry Group (EMIG) (EUCOPE)


    NEIL GRUBERT Global Market Access Consultant, Independent


    G. NARAYANAN Biologicals Advice


    LINCOLN TSANG Arnold & Porter


    MARIE MANLEY Bristows


    NICK BOSANQUET Imperial College

08th and 09th June 2016, Pestana Chelsea Bridge Hotel, London UK

“Critical guide for successfully identifying your pricing, reimbursement and market access strategies”

Sponsors & Exhibitors
  • Conference Info
  • Day One
  • Day Two
  • Speakers
  • Sponsors
  • Partners
  • Sponsorship Opportunity
  • Delegates
  • Pricing
  • Venue
  • Testimonials
  • Presentations
  • Gallery


Pricing and market access (P&MA) are key concerns for the pharma industry as healthcare budgets remain to tighten and the value of advanced drugs, particularly in areas of high unmet need, becomes infinitely solider to assess. Pharma and payers are forceful to find a balance between budget management and patient access. Pricing has consistently been a pressure point. This is even more risky today with the shift to specialty products and treatment of rare diseases. As P&MA becomes central to commercialization, P&MA as a function is crucial to achieving leadership through this challenging environment. However, it is vital that we not just identify trends – but as an industry we stay ahead of them and even influence their evolution. P&MA cannot be just a source of expertise within pharma – it needs to be a active leader of business results, shaping the future and engaging with stakeholders, and influencing decision-making.

This conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. Following a raft of health policy reforms impacting pharmaceutical pricing in almost every major country in the EU, it gives me great pleasure in welcoming all of you to the Virtue Insight’s 2nd Annual Pharma Pricing, Reimbursement & Market Access 2016.  I wish and pray that all our efforts will be beneficial to our industry and to our country at large.



  • Preparing your best market access strategy
  • EU and US policy challenges for market access: Stepping ahead
  • Unrivalled opportunity to expose and address the market access challenges facing the industry
  • Current & future - Challenges & opportunities in pharma pricing, reimbursement & market access
  • Improving patient and market access through the development of targeted value propositions, comprehensive contract assessment
  • Measurement strategies through to in-depth knowledge regarding payer formulary coverage trends
  • How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?
  • Understanding - payers’ perspective
  • Advocating and collaborating with payers for value in a new era
  • Creating a robust patient services and reimbursement support program for biosimilar products
  • Prioritising Patients! - Adding value through an innovative patient-centered approach
  • Understand how price affects market access and learn on how to set prices for optimal access and returns.
  • New drugs are failing to gain reimbursement from payers/HTAs at an alarming rate, despite being approved by regulators
  • Evidence Generation - The strategic rigor and creativity applied to evidence generation
  • Impact of social media and digital analytics
  • Developing risk-sharing reimbursement models and value based pricing
  • Patient engagement and adherence within the environment
  • Explaining how to use the data sources and observational research for effective safety analysis
  • Dwell ahead of regulatory developments & improving your strategies in a cost effective way in EU, US
  • Accelerating new medicine introduction in developing world & overcoming challenges
  • Be part of a major networking opportunity



Senior Vice Presidents, Vice Presidents, Senior Executives, Global Heads, Heads, Directors, Senior Managers, Managers of:

  • Pricing
  • Reimbursement
  • Market Access
  • Commercial Pricing
  • Pricing Strategists
  • Health Economics
  • Outcomes Research
  • Regulatory Affairs
  • Governmental Affairs
  • Public Affairs
  • Public Policy Directors
  • Operations
  • Governmental bodies
  • Regulatory bodies



2nd Annual Pharma Pricing, Reimbursement & Market Access 2016 – “Critical guide for successfully identifying your pricing, reimbursement and market access strategies”

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. You cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.  Devise an immediate action plan for your strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 – Chairperson opening remarks 

OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health



09:40 – Access to new Diabetes medications in Germany & Key European Markets

  • Similarities and differences in HTA processes
  • National vs regional price/volume control
  • Economic differences in healthcare systems
  • Price referencing and implications  

OLIVER STAHL, Sr. Director Corporate Affairs & PRA, Eli Lilly


10:20 – AMNOG and its international implication

  • International Reference Pricing
  • Differential Pricing
  • Orphan medicinal products in HTA
  • International pilots for early access

ALEXANDER NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

11:00 – Morning Coffee/Tea & Discussion


11:20 – Morning Keynote Panel Discussion: Current & future - Challenges and Opportunities in pharma pricing & market access

  • Staying ahead in the race - Update on pricing and market access in EU, USA & RoW 
  • Current formulary trends within the pharmaceutical and biotechnology landscape
  • Vital areas for improving market access – for industry & payers
  • “Value versus Price” conflict - truly understand how and why payers reimburse, and how you can align your pricing efforts accordingly
  • The future of pharma access, evidence & pricing: how are you preparing for market access in 2020?



OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health



KEN WALSH, Senior Principal, Global Payer Strategy Consulting, Evidera
LESLIE GALLOWAY, Chairman Ethical Medicines Industry Group (EMIG) & Vice President (EUCOPE)
SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting
LINCOLN TSANG, Partner, Arnold & Porter


12:00 – Advocating and collaborating with payers for value in a new era

  • What is the mind-set that is required to demonstrate value to payers ?
  • What is the role of RWD v RCT data ?
  • Influence of National HTA Payers v Regional Payer Restrictions
  • Opportunities for better collaboration with payers
  • Creating collaboration with value based agreements
  • Co-creation of Value within the Health Economy
  • Innovative Contracting, Cost Effectiveness v Affordability

OMAR ALI, Pharmacy Consultant, QIPP Adviser Payer Network

12:40 Networking luncheon 


14:00 – Panel Discussion: Launch success for specialty products in today’s managed markets environment – Strategy, Data and Partnerships

  • How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?
  • Market access and pricing issues
  • Analyzing successful strategies, payor value proposition development, pricing, and contracting
  • Ensuring effective and efficient dialogue between your external stakeholders and relevant internal functions
  • Making formulary decision to secure innovative, high-quality coverage in times of exploding costs
  • Setting benchmarks and defining endpoints – data mining and partnerships analysis


OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health



OMAR ALI, Pharmacy Consultant, QIPP Adviser Payer Network 

ANNA FORSYTHE, Sr. Director, Global Head, Global Value and Access Strategy, Eisai (USA)
NICK BOSANQUET, Professor of Health Policy, Imperial College 

NEIL GRUBERT, Global Market Access Consultant, Independent


14:40 – Current development of prices and reimbursement in Germany

  • AMNOG as learning system
  • Impact on patients’ access to new pharmaceuticals
  • Pharma dialogue and Outlook on AMNOG

MARCO PENSKE, Head of Market Access &. Healthcare Affairs, Boehringer Ingelheim


 15:20 – Afternoon Tea/Coffee




15:40 – HTA and decision making in the reimbursement of medicines: How to pre-empt HTA issues early in Development

  • New drugs are failing to gain reimbursement from payers/HTAs, despite being approved by regulators
  • Incorporating market access and pricing excellence into the activities of your HEOR departments for a more efficient  value demonstration strategy
  • Case study

PATRICK MOLLON, PMHE, Health-Economics & Outcomes Research Consultant

16:20 Evidence Generation - The strategic rigor and creativity applied to evidence generation

  • Evidence reviews, meta-analyses, synthesis, and reporting
  • Data analytics and real world evidence
  • Health economic modelling and economic evaluation
  • Value messaging and dossier development

ANNA FORSYTHE, Sr. Director, Global Head, Global Value and Access Strategy, Eisai (USA)

17:00 Chairperson’s closing remarks and end of conference

17:10 – 18:30 Networking Drinks Session

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 – Chairperson opening remarks 

 OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health




09:40 – Risk Management - Strategic partnerships and engagement with integrated health systems and ACOs

  • Value-based contracting agreements
  • Aligning value with your evolving integrated customers and ACOs as reimbursement reform moves to episode-based payments, care bundling, and risk sharing
  • Rethink your strategy, tactics, and tools to integrate sales, marketing and managed markets capabilities,
  • Discuss actionable opportunities for manufacturers to support ACOs and Integrated Health Systems
  • How to shape your commercial strategies in terms of risk assumption, reimbursement, and prescription medication management
  • How to best provide financial incentives to payers in return for higher formulary placements

DOMINIK DZIURDA, Market Access Director - Europe, GSK

10:20 – Canada: A Brave New World for Pricing, Reimbursement and Market Access

  • Overview of Canadian health care system and pharmaceutical funding
  • Pan Canadian Pharmaceutical Alliance (pCPA): “national” risk sharing agreements, new biosimilar and  generic pricing policies
  • Price regulation / PMPRB: new pricing rules coming for patented medicines
  • Private drug plans: new HTA policies and requirements for risk sharing agreements
  • HTA: CADTH/CDR/pCODR, INESSS – updates on recent initiatives
  • Prospects for a “National Pharmacare Program”
  • Outlook for Canadian pricing and public / private reimbursement policies

W. NEIL PALMER, President & Principal Consultant, PDCI Market Access

11:00 – Morning Coffee/Tea & Discussion




11:20 – Payer’s perspective – What are they looking for?

  • Embracing payer expectations by introducing them early in product development
  • Pricing and reimbursement policies in the light of the financial crisis
  • How should be the collaboration with payers?
  • Full-filling HTA requirements and demonstrating value to payers
  • Understand payer preferences on patient pathway optimization
  • Detect and develop solutions to co-create incremental value with external stakeholders including payers
  • The essences of what payers want in order not to view pharmaceuticals as commodities

JOSE LUIS SANCHEZ CHORRO, Head of Market Access Hematology and Inmunology Spain & Portugal, Baxalta


12:00 – Opportunities and challenges in promoting marketing access in emerging markets

  • Expanding access through partnerships with payors
  • Role of government in promoting access in emerging markets
  • Challenges in managing public/private partnerships

NEIL GRUBERT, Global Market Access Consultant, Independent

12:40 Networking luncheon

13:50 – Challenges faced by bio-pharma companies in dealing this the HTA authorities and how this affects their commercial and legal strategy to secure an effective market access?

  • The current HTA environment – impact of HTA on Commercial Strategy
  • The UK example: what is NICE about?
  • Existing Jurisprudence – where are we going?
  • What is the relationship between HTAs and the regulatory agencies?
  • What does the future hold?

MARIE MANLEY, Partner, Head of the Regulatory Practice, Bristows



14:30 Additional benefit with patient reported outcomes – what are the requirements?

  • The concept of HRQoL in the AMNOG process
  • Challenges in measuring and analyzing HRQoL in clinical studies
  • How to achieve an additional benefit with HRQoL

FRIEDHELM LEVERKUS, Director Health Technology Assessment & Outcomes Research, Pfizer

15:10 – Afternoon Tea/Coffee

15:30 Biosimilars – how can they contribute to lower costs and more treatment?

  • What is the future impact of biosimilars?
  • Will biosimilars have a chilling effect on prices of new drugs?
  • Lessons learned – successes and failures

STEINAR MADSEN, Medical Director, Norwegian Medicines Agency




16:10 – Panel Discussion: Regulatory updates and development

  • Understanding the effects of forthcoming regulatory changes on your access, pricing and reimbursement efforts
  • Possible increase synergy between HTA and regulatory agencies – Opportunity or challenge for medical devices?
  • Evolutions in global price management
  • How are we to be working with payers and governments?
  • Gain clarity on issues of standards for licensure and indication extrapolation
  • Vision for 2020

OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health


STEINAR MADSEN, Medical Director, Norwegian Medicines Agency

G. NARAYANAN, Managing Director, Biologicals Advice

MARIE MANLEY, Partner, Head of the Regulatory Practice, Bristows

16:50 17:00 – Chairperson’s closing remarks and end of conference 

OYVIND MELIEN, Chair of Secretariat, Norwegian Directorate of Health


Head of Market Access & Healthcare Affairs

Boehringer Ingelheim

Dr Marco Penske has been the Head of Market Access and Healthcare Affairs of Boehringer Ingelheim since 2011.

Dr Marco Penske has studied Economics at the University of Mainz with focus on Health Economics and Statistics. Afterwards, he was working as a Research Assistant at the chair of Finance and Economics at the same university. After his promotion about questions of financing healthcare systems and the expansion of capital covered elements, he was employed at a business consultancy company. In 2007 he has joined Boehringer Ingelheim. His current responsibilities are among others the benefit assessment and price negotiation after AMNOG, the development of pricing strategies and contract models for pharmaceuticals and the healthcare affairs activities. Moreover, he is an active speaker on congresses and working as a lecturer.


Sr. Director, Global Head, Global Value and Access Strategy

Eisai (USA)

Dr. Anna Forsythe is Senior Director and Head of Global Value and Access Strategy at Eisai Inc. Anna’s team has a responsibility for understanding payer perspectives and developing the market access strategy for the entire Eisai portfolio, including the payer value proposition, pricing strategy, outcomes research, health economics and reimbursement support across all disease areas and all markets.

Anna has more than 19 years of experience in global product commercialization and strategic drug development, market access, HEOR, pricing and reimbursement across major pharmaceutical companies covering multiple therapeutic areas. Anna is a frequent and contributor to forums, articles, conferences and a guest lecturer at Rutgers University Business School addressing issues related to value of therapies, health economics evaluations and access to medicines.

Previously to Eisai, Anna was a Director of Worldwide Health Outcomes, Value and Access for Novartis  Oncology and prior to that, she held positions of increasing responsibility at Novartis, Schering AG and Savient pharmaceuticals. Anna has a doctorate degree in Pharmacy, a Master of Science in Health Economics and Public Policy and a Master in Business Administration.


Director Health Technology Assessment & Outcomes Research


After studying statistics at the University of Dortmund (Germany) in 1988, Friedhelm Leverkus worked at the Social Research Centre in Dortmund.

In 1991 he started his career at Pfizer Pharma GmbH as a biometrician. In this capacity he planned and analyzed clinical studies. In 1995 he was named Head of Biometrics. He was in charge of biometric support for clinical trials and NIS studies.

He leads the Health Technology Assessment Group at Pfizer Germany, which is responsible for HTA and outcomes research, since 2010. The group is mainly responsible for development of AMNOG-Dossiers.

For years he’s in an active cooperation with a subcommittee for vfa (Die forschenden Pharma-Unternehmen, Germany).


Pharmacy Consultant

QIPP Adviser Payer Network

Qualified with a hospital pharmacy background, Omar has been working as the Formulary
Advisor for Surrey & Sussex Healthcare NHS Trust for nearly 15 years. He sits on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network.

Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer &
Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date (prescribing, medicines management & health economics).

He is an Editorial Content Adviser to Guidelines and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology. In 2010, Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 5 years and in 2016 was appointed Panel Member for the newly formed Adoption & Impact Program for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US.

Omar heads up an exciting new ‘Medicines Management Payer Network for 2016/17; Qipp adviser aims to provide Payers with a peer review of New Medicines & Pharma value propositions in a rapidly accessible, user friendly format. Most recently, he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery.


Medical Director

Norwegian Medicines Agency


Market Access Director - Europe



Sr. Director Corporate Affairs & PRA

Eli Lilly

Oliver joined Eli Lilly in June 2001. He graduated from the Justus-Liebig University in Giessen as Diplom Kaufmann degree. Before moving to the Corporate Affairs function he held various assignments in the financial function of Eli Lilly, most recently as the CFO for the Central European cluster. (Czech republic, Slovakia and Hungary). Beginning of 2012 he returned to Germany and shifted from the finance function to Market Access for Germany and since the middle of 2014 Corporate Affairs & PRA for Austria Switzerland and Germany. His responsibility covers all activities that lead to a successful Health Technology Assessments and reimbursement for the Lilly portfolio as well as the relationship to payer customers at national, regional and local levels.


Senior Principal, Global Payer Strategy Consulting


Ken leads the London based Payer Strategy Consulting team as a Senior Principal

Ken brings 13 years of global market access and pricing experience spanning both industry and consulting roles based in the US, EU and Emerging Markets

Ken recently joined Evidera from GlaxoSmithKline where he was head of pricing across their portfolio in the Emerging Markets Asia Pacific (EMAP) division based at their HQ in Brentford

Prior to joining GSK, Ken was head of Global Pricing and Market Access for Sandoz’s Biosimilars and Oncology Injectibles Business Unit based at their HQ in Munich

Prior to moving into industry Ken spent 10 years in consulting based in the USA and Asia with companies including Bridgehead, Kantar Health, GfK Healthcare and Cambridge Pharma

Ken holds a MA in Economics from Heriot-Watt University and an MSc in Finance from the Cass Business school, London


Head of Market Access Hematology and Inmunology Spain & Portugal


Participation in the Inter-Ministerial Committee on Drug Prices in the Ministry of Health, Social Services and Equality

Member of the Regional Committee of Hospital Pharmacy Extremadura

Member of the Joint Commission of Pharmacy in Extremadura with the Official Colleges of Pharmacy.

Participant in the working group for Innovative Medicines, Ministry of Health

Board Member of Rare Disease Commission in Extremadura Health Service

Member of the Advisory Commission of Diabetes in Extremadura Health Service

Head of Market Access in Baxalta Spain



Health-Economics & Outcomes Research Consultant

Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in Lyon’s School of Medicine, France where he also gained a Masters Degree in Medical and Biological Sciences, including Pharmacology, Psychology and Medical Statistics. Prior to this, he received an MBA from the Superior School of Business and Administration and Economics (ESSEC) in Paris.

He then worked as a Clinician, practicing General Medicine as well as being a Registrar in Emergency Medicine and Intensive Care in an University Teaching Hospital in Lyon, France.

He started his Pharmaceutical Career in Pfizer Central Research as a Clinical Research Physician and then joined the Outcomes Research Division where he held a number of successive positions in the Product Development Group and the Medical division. He is currently Worldwide Director, Health Economics and Outcomes Research in the Global Patient Access Division of Novartis Pharma AG. Patrick has extensive experience in developing and implementing Health Economic strategies to support developmental compounds in a number of therapeutic areas, including Cardiovascular, Urology, Anti-Virals and Dermato-Immunology, leading the value identification and demonstration efforts for Market Access and Health Technology Assessment from a Global perspective. As such, he is leading the development of Patient Reported Outcomes tools, Health-Economic and Budget-Impact models, Value Dossiers and Real World Evidence.

Patrick has a number of publications in the area of Health-Economics and Outcomes Research, His main interests are in health-economic modelling methods and applications as well as patient-reported outcomes and decision-making.


Chair of Secretariat

Norwegian Directorate of Health


Chair Secretariat for Managed introduction of novel health technologies in specialist health care of Norway, Norwegian Directorate of Health

Background (education, previous positions):

MSc (cell biology), MD, PhD (pharmacology)
Specialist in Clinical Pharmacology
Head of Dept. Clinical Pharmacology and Clinical Research Unit, National Hospital, Oslo, Norway
Chair of Drug and Therapeutics Committee, National Hospital, Oslo, Norway
Chair of Drug Therapeutics Committee, Health Region South East, Norway
Chair Specialist Committee in Clinical Pharmacology, Norwegian Medical Association
Chair Norwegian Society of Pharmacology and Toxicology
Chair Subgroup OECD GSF Education, Training, Infrastructure and Patient involvement in Clinical Trials
Member from Norway in European HTA Network (HTAN)


President & Principal Consultant

PDCI Market Access

Neil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded) in 1996.    At PDCI, he leads a senior team of market access professionals with pricing & reimbursement engagements focusing primarily on the Canadian market.  Neil is also Adjunct Assistant Professor at the University of Southern California School of Pharmacy graduate program in Health Care Decision Analysis where he lectures on health technology assessment, pricing and market access from a global perspective. Neil served as global vice president for pricing and reimbursement with RTI Health Solutions of RTP North Carolina from 2006 – 2009.  He previously worked with the Canadian Patented Medicine Prices Review Board (PMPRB), the Health Division of Statistics Canada and the research group of the Kellogg Centre for Advanced Studies in Primary Care in Montreal.  A graduate of the University of Western Ontario, Neil has written extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.


Chief Medical Officer

Frontline Pharma Consulting

Dr Eisen graduated from Cambridge University in 1980 and studied clinical medicine at St Bartholomew’s Hospital Medical School in London.  He has postgraduate medical qualifications in Surgery and in Pharmaceutical Medicine and now has over 25 years’ experience in pharmaceutical regulation and pharmaceutical medicine.  He has worked in several senior positions in both Government and the Pharmaceutical Industry, most recently having been Chief Medical Officer for Teva Pharmaceuticals Europe for 5 years.

In 2011 he set up his own Company, Frontline Pharma Consulting Ltd providing independent advice to pharmaceutical and financial companies on all aspects of research, pharmaceutical regulation and drug safety, and covering innovative products, biosimilars and generics in all therapeutic areas.  He also works on contract in interim senior management roles, including Chief Medical Officer, Medical Director, Clinical Research Director and as a Senior Safety Physician/QPPV. 

Contact details:


+44 7921 495663 (mobile)
+44 0208 3648426 (office)


Secretary General

European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Since 2009, Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as lawyer in his own law firm in Düsseldorf (www.natz-law.com). From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.


Chairman & Vice President

Ethical Medicines Industry Group (EMIG) (EUCOPE)

Leslie built a successful career over 40 years in senior management roles in both the pharmaceutical and medical device industries, culminating in the successful turnaround of a pharmaceutical business.

He was elected EMIG Chairman in 2005 and has been instrumental in the metamorphosis of EMIG from being a business/networking group to the influential trade association it is today. In 2005, EMIG began with 17 Member Companies and today, has 250+, of which, 90% choose to be represented only by EMIG. Consequently, EMIG represents 40%-50% of UK branded medicines.

In July 2014, Leslie was elected Vice President of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He was Vice Chairman of the NICE Project Development Group for Local Formularies Good Practice Guidance, a member of the NICE Medicines Optimisation Guidance Development Group and was recently appointed as an Expert Adviser to the NICE Centre for Clinical Practice. He is currently a member of the Accelerated Access Reference Group and was a member of the Cancer Drugs Fund Working Group. He has published numerous articles, is a frequent speaker at national and international seminars, a Member of the Scottish Government’s Strategic Engagement Group, a Member of MENSA and is a visiting lecturer at the University of Cambridge.


Global Market Access Consultant, Independent

Neil Grubert is a pharmaceutical market access specialist with 26 years of experience tracking the global prescription drug and self-medication markets. He has authored more than 150 reports on market access, covering 20 mature and emerging markets, multiple therapeutic areas, and numerous industry issues, including a recently published study on key market access trends in Europe. Neil is an experienced public speaker who has chaired events and delivered numerous presentations at conferences, seminars, webinars and training workshops, including bespoke programmes commissioned by senior executives at top ten pharmaceutical companies. He is currently working as an independent consultant and is developing a series of multi-client training programmes in market access. Neil previously spearheaded the development of Decision Resources Group’s international market access business, most recently as Vice President of Global Market Access Insights. He has also done contract work on early-stage market access for GlaxoSmithKline.


Managing Director

Biologicals Advice

Dr Narayanan has substantial regulatory expetise in the area of biologics, advanced therapies and biosimilars. He worked at MHRA during 2001 – 2013 and was Head of the Biotechnology unit and Expert Medical Assessor. He was also member of the Committee for Advanced Therapies (EMA/CAT 2009 – 2013), Scientific Advice Working Party (CHMP/SAWP 2009 - 2013), Biosimilar Working Party (EMA/BMWP) and Gene Therapy Working Party. He is Biologics and Advanced Therapies expert at NDA Regulatory Science. He is also Managing Director of Biologicals Advice Limited and provides independent advice on all aspects of development of medicinal products with a special interest in advanced therapies. He is on the scientific editorial board of Gene Therapy Clinical Development journal. He previously worked at Reckitt Benckiser, UK and Chiron Corporation, CA, USA. He has dual specialist postgraduate qualification in general internal medicine and pharmaceutical medicine.



Arnold & Porter

Lincoln  is a partner based in Arnold & Porter’s London office. His practice is focused on providing strategic cross-border regulatory, compliance, enforcement and litigation advice to the life sciences industry. He regularly undertakes internal investigations for companies. He also advises trade associations, foreign governments and charity/not-for-profit organizations. By ministerial appointment, Lincoln is currently a Commissioner of the British Pharmacopoeia Commission chairing its biologicals/biotechnology sub-committee and nomenclature committee; and has served as a non-executive member of the Regulatory Oversight Committee of the now defunct UK Health Protection Agency; a non-executive director of the board of the National Institute for Biological Standards and Control; a member of the Ministerial Industry Steering Group for pharmaceuticals. Lincoln was with the UK regulatory authority for nearly 13 years and latterly as the head of biological/biotechnology responsible a wide range of domestic and international legislative and policy matters. During his tenure, he served as advisor to the European Medicines Agency, the European Commission, and the World Health Organisation on international trade issues, and represented the European Commission at the International Conference on Harmonisation on matters relating to biological products. Most recently, he served as special advisor to the Council of Europe in developing the MediCrime Convention against counterfeited medical products. He was a member of the Council of the University College London School of Pharmacy and its governance and audit committees. He chaired the UK Bioindustry Association’s Regulatory Affairs Committee for two terms.


Partner, Head of the Regulatory Practice


MARIE MANLEY is a Partner and head of the IP Regulatory Department at Bristows LLP (London).  She advises on both contentious and non-contentious matters, focusing on regulatory and competition law in the bio-pharma, medical devices, cosmetic and food sectors; including life cycle management issues, advertising and product liability.

Marie represents leading bio-pharma companies in litigation before the English and EU courts.  Recently, Marie successfully represented both Laboratoires CTRS before the General Court in relation to the Commission’s refusal to grant a marketing authorisation for an orphan medicinal product (Case T-301/12); and Seattle Genetics Inc. in an SPC case before the Court of Justice (C-471/12); as well as Shire Pharmaceuticals which secured a Paediatric extension. Marie also regularly co-ordinates EU and overseas litigation. Marie is also representing a pharma company against a decision of the EU Commission for breach of competition rules, as well as representing them in a damage action before the English Courts.

Marie also represents pharma companies before UK and EU institutions (EMA, MHRA, NICE, PMCPA DOH and the European Commission).  For example, Marie successfully represented Clinuvel Pharmaceuticals before the EMA in relation to their application for SCENESSE®, a breakthrough drug.

Marie is Chairperson of the Legal Affairs Community for DIA. Marie is considered as a leading practitioner for regulatory law and is described by clients as a “regulatory superstar”. She is recommended in Legal 500, Chambers and Partners; also London Top 100 & London Top 50 Women and EU Law & Super Lawyers UK(2013).


Professor of Health Policy

Imperial College

Nick Bosanquet, Emeritus Professor of Health Policy Imperial College. Founder member of the Centre for Health Economics University of York. Special Advisor to the Commons Health Committee 2001-10. Publications include  “Family  Doctors and Economic Incentives” and “The Economics of Cancer Care.” Director of TBS GB since 2007. Chief Investigator  for GSK on part of Salford Lung Study. Research on international comparisons of COPD programmes. N.Bosanquet et al. The Effectiveness Gap in COPD. PrimCare Respir J 2013. 22(2) 209-213.


Virtue Insight

Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.



Pharma Phorum

Going to meet

Conference Locate


You Tube



Linked in

Partnering with Virtue Insight means more than making the right contacts. It means being an insider. It means being connected to the right people with the right level of influence, and it means you are allied with a globally respected organization and leaders in the industry.?

Sponsorship, exhibiting and advertising packages are designed to provide a solid platform to help you stand out and make an impact. Our programs allow you to achieve your marketing goals and deliver a maximum return on your investment. We have developed convenient and customizable packages to help your organization meet its objectives and reach your target market.

Why Sponsor / Exhibit:

PROFIT: To Maximize
MARKET SHARE: Defending and Increasing Market Share
COMPETITION: To attach and defend against competition


  • Generating sales leads
  • Build brand image
  • Maintaining customer relations
  • Consolidating business relationships
  • Accessing new and emerging markets
  • Obtaining technical knowledge
  • Leverages the events extensive marketing campaign to add value to your organisations marketing strategy and budget leading up to the event
  • Live product demonstration to test market responses
  • Facilitating quick market penetration
  • Reach important targeted commercial prospects face to face in a social, relaxed environment. The ideal platform to build strong business friendships Strengthen your market position

Our conferences offer not only a unique combination of benefits (as listed above) to enable the sponsor/exhibitor to communicate the message but also a major opportunity that other forms of selling or media cannot provide.

Contact Us Today

Email - sponsor.uk@virtueinsight.com
Tel: +44-2036120886

Email - sponsor@virtueinsight.com
Tel: +91 44 64536444

Our highly researched conference agenda delivers all the latest information and our world-class speakers attract delegates from around the world to attend. We aim for our attendees to be equipped with knowledge of latest developments and enable them to network with the industry key personnel.

What is the format of our conference programme?
The conference programme consists of world-class keynote addresses, case study presentations and panel discussions.

What are the benefits of attending?

  • Meet your peers in an interactive, discussion-based format designed to maximize knowledge transfer and networking
  • Enjoy our informal networking at drinks and lunch
  • Meet the leading solution providers in the market to forge partnerships and discover solutions
  • Receive electronic versions of the conference documentation for use of reference post-event.
  • Get ideas for?training topics?that you might want to present as professional development sessions to others in your workplace.
  • Observe speakers from the perspective of seeing what works really well so you can learn new public speaking techniques and strategies that you can apply when doing your own presentations.
  • Learn what not to do in presentations if you end up sitting through any sessions that fail to be engaging or informative.
  • Delegates also benefit from discounted rates onfuture event attendance

For more information or to register at the event please contact us TODAY:

Contact Us Today

Email - delegate.uk@virtueinsight.com
Tel: +44-2036120886

Email - delegate@virtueinsight.com
Tel: +91 44 64536444


Introductory Offer (3 delegate places for the price of 2):- You can simply email or call and book your conference delegate seats on – TEL: +44 2036120886. Email – delegate.uk@virtueinsight.com

Standard Registration:-  Conference Delegate Pass (£ 1100 + VAT per delegate) – You can simply email or call and book your conference delegate seats on – TEL: +44 2036120886. Email – delegate.uk@virtueinsight.com

Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to – TEL: +44 2036120886. Email – sponsor.uk@virtueinsight.com

Pestana Chelsea Bridge Hotel

Address: 354 Queenstown Rd, London SW8 4AE, United Kingdom
Phone:+44 20 7062 8000
Click here for (Map)

Testimonials from our past Biosimilars Congregations


Very informative and Comprehensive - Associate Professor, Lakehead Universit

Very relevant and current content - Principal Research Associate, BresMed Health Solution

Really interesting and relevent with speakers from a good variety of backgrounds - Graduate Health Economist, BresMed Health Solutions

A very insightful conference – Elucidated key legal, Clinical and Regulatory issues and recommendations across multiple regions - Business Development, Adaptimmune

DOWNLOAD W Neil Palmer_PDCI Market Access
DOWNLOAD Steinar Madsen_Norwegian Medicines Agency
DOWNLOAD Patrick Mollon_Health-Economics and Outcomes Research Consultant
DOWNLOAD Oyvind Melien_Norwegian Directorate of Health
DOWNLOAD Oliver Stahl_Eli Lilly
DOWNLOAD Neil Grubert_Global Market Access Consultant
DOWNLOAD Marco Penske_Boehringer Ingelheim
DOWNLOAD Jose Luis Sanchez Chorro_Baxalta
DOWNLOAD Hilary Jones_Bristows
DOWNLOAD Friedhelm Leverkus_Pfizer
DOWNLOAD Anna Forsythe_Eisai
DOWNLOAD Alexander Natz_European Confederation of Pharmaceutical Entrepreneurs

Conference pictures can be viewed and downloaded at our official Virtue Insight facebook page

Link - Click Here

You have been registered successfully!
Enter Password
Submit Close